NovaShunt Starts Its Pivotal Clinical Study PIONEER To Demonstrate The Clinical Value Of The AFS System
NovaShunt announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and performance of the Automated Fluid Shunt in patients with ascites and diuretic Resistance. The study is designed to evaluate the safety and performance of the Automated Fluid Shunt (AFS) System in replacing the need for paracentesis, the standard therapy for patients with refractory ascites. Secondary parameters in the study are concomitant reduction in the need for medication, health care costs (hospitals stays, treatment) and patients' quality of life.
Janet Bunch of Chicago had just experienced another "excruciating" bout of diverticulitis, an inflammation of the pockets in the lining of the colon. "It was the second time in 19 months and the pain was worse than you could imagine, " said Bunch, 64, a resident of Chicago. Mild cases of diverticulitis can be treated with changes in diet, rest and antibiotics. However, Bunch's condition was more serious and the chances of recurrences were high. Her doctors at Loyola University Health System said her best option would be surgery to remove the inflamed section of colon. Upon learning that her surgeon was going to perform her procedure laparoscopically, involving a camera and small incisions, she went online to learn as much as she could about the technology.
Researchers at National Jewish Health have discovered how the virulent food-borne bacteria Listeria monocytogenes induces infected immune cells to sabotage their own defensive response. The studies offer insight into host-pathogen interactions and suggest potential therapeutic targets for food poisoning, tuberculosis and autoimmune diseases. In the Feb. 15 issue of the Journal of Experimental Medicine, Laurel Lenz, PhD, and his colleagues report that macrophages infected by the bacteria Listeria release interferon-Î Î (IFN- Î Î ), which makes them and nearby immune cells unresponsive to activation signals. This reduces immune resistance to the bacteria, which causes thousands of cases of food poisoning -- and more than 500 deaths -- each year in the United States.
Helicobacter pylori (H. pylori) is the causal agent of chronic gastritis, ulcer and gastric cancer. It has the potential to persist in the human stomach for decades, sometimes causing neither harm nor clinical symptoms. Nevertheless, on some occasions, depending on the host immune system and the strain causing the infection, the outcome can be very serious. To maintain the infection, the bacterium must adapt to survive the host defences. One way to accomplish this is to sequentially change the external proteins on the bacterial surface. A research article published in the World Journal of Gastroenterology addresses this. As part of a search for adequate antigens to generate a vaccine against H.
Helicobacter pylori (H. pylori) are considered to be the most important etiological agents of chronic gastritis. The eradication of H. pylori depends on the combination of antibiotics and acid suppression drugs. Unfortunately, the side effects of antibiotics reduce the curative effect and treatment compliance. Probiotics provides an alternative method which can inhibit H. pylori infection efficiently without antibiotics associated side effects. A research team from China investigated the potential anti-H. pylori and anti-inflammation in vivo effects of two lactobacillus strains from human stomach. Their study was published in the World Journal of Gastroenterology.
The clinical outcome of gastric disease may involve differences in the prevalence or expression of bacterial virulence factors. Contrary to Asian studies, Western studies have disclosed associations between the presence of babA2 gene and gastric cancer. Evidence concerning BabA adhesin-associated genes is insufficient in Costa Rica, where the incidence of gastric cancer is very high, similar to Japan. The babA2 gene, which encodes BabA, may play a role in the development of gastric cancer in the Costa Rican population. A research article published in the World Journal of Gastroenterology addresses this. Using data from 95 H. pylori-positive Costa Rican patients, and 95 H.